City
Epaper

AstraZeneca jab authorised for all age-groups, says EMA

By IANS | Updated: June 14, 2021 17:30 IST

Brussels, June 14 AstraZeneca's Covid-19 vaccine remains authorised for all populations, European Medicines Agency (EMA) has said.The ...

Open in App

Brussels, June 14 AstraZeneca's Covid-19 vaccine remains authorised for all populations, European Medicines Agency (EMA) has said.

The clarification camme after Italian newspaper La Stampa earlier quoted Marco Cavaleri, head of the EMA's vaccine strategy, recommending a stop to administration of AstraZeneca's Covid shots in Europe to people aged over 60 and younger age groups, amid fears over very rare blood clotting.

"Misinformation is making the rounds today. This is the situation: Benefit/risk balance of AstraZeneca #Covid19 vaccine is positive and it remains authorised for all populations," the EMA said in a tweet on Sunday.

Cavaleri was also quoted by the newspaper advising the use of the Johnson & Johnson vaccine preferentially for the over-60s.

The European Union has approved AstraZeneca and Johnson & Johnson vaccines for all populations aged 18 and above. However, both viral vector-based jabs have been marred by various reports of rare blood clots.

The EU has also authorised Pfizer-BioNTech and Moderna's mRNA based Covid-19 vaccines.

Asked by the newspaper whether it would be better to stop using AstraZeneca for all age groups, Cavaleri had said: "Yes, and it is an option that many countries, such as France and Germany, are considering in the light of the increased availability of mRNA vaccines."

"However, incidents were very rare after the first dose. It is true that there is less data on the second dose, but in the United Kingdom it (the vaccination programme) is going well," he added.

On June 11, Italy restricted the use of AstraZeneca doses to those aged 60 years and above, after a teenager who had received the shot died from a rare form of blood clotting.

In March, the two-dose vaccine was briefly halted by many European countries, including Italy, over concerns about the rare blood clotting problems.

But, its usage was resumed in April, after the EMA said its benefits outweighed any risks.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Marco cavalerifranceBrusselsAstrazenecaAstrazeneca plc.Brussels capital regionEuropean medicines agencyAstrazeneca plcAstra zeneca
Open in App

Related Stories

InternationalFrench President Emmanuel Macron Invites More Chinese Investment in Europe Amid US Trade Tensions

LifestyleHalloween 2025: Date, History, Meaning, and Why the World Celebrates the Spookiest Night of the Year

InternationalCyber Attack Halts Check-ins and Flight Boarding at European Airports, Including London’s Heathrow

InternationalAfter Nepal, Now France: Vehicles Torched, Train and Road Traffic Disrupted as 'Block Everything' Protest Turns Violent

InternationalParis: 3 Injured, One Critical After Car Drives Into Crowd at Champs-Elysees During PSG Champions League Win Celebration; Video Surfaces

Health Realted Stories

HealthIndia to boost biosimilar insulin, CGM manufacturing as Global South looks for support

HealthIndia clocks unprecedented foodgrain output, boosts institutional support to farmers

HealthIndia tightens watch on GLP-1 drugs amid safety and misuse concerns

HealthIndia’s millet push receives dual boost at technology and grassroots levels

HealthUK heart rhythm expert now performing procedures in India